Anemia, Hemolytic: all 87 studies

Page 1 of 1. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.

• Native T1 Mapping and ECV in Chronic Hemolytic AnemiaNot yet recruitingNCT07882303
• New CBC Parameters in Diagnosis of Hereditary SpherocytosisNot yet recruitingNCT07842718
• A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHANot yet recruitingNCT07738822Phase 1/2
• Congenital Hemolytic and Dyserythropoietic AnemiasRecruitingNCT07649213
• High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety StudyNot yet recruitingNCT07612345Phase 1
• Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell DiseaseRecruitingNCT07566494Phase 1
• Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease EndotypeRecruitingNCT07282210Phase 2
• National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic AnemiaRecruitingNCT07019038
• UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune DiseasesNot yet recruitingNCT06978738Phase 1
• UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Autoimmune Hemolytic AnemiaNot yet recruitingNCT06920446Early Phase 1
• A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT06770504Phase 1
• Predisposing Factors for Liver Diseases in Patients With Chronic Hemolytic AnemiaNot yet recruitingNCT06743854
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.RecruitingNCT06733610Phase 1
• Study of Acquired Hemolytic Anemia in Adult Hospitalized PatientsNot yet recruitingNCT06708728
• CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of TherapyRecruitingNCT06212154Phase 1
• The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
• OBS'CEREVANCE: French Cohort of Pediatric Autoimmune CytopeniaRecruitingNCT05937828
• Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune NeutropeniaRecruitingNCT05931718
• Zanubrutinib in the Treatment of Relapsed/Refractory wAIHARecruitingNCT05922839Phase 2
• A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitationNCT05777993Phase 4
• Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
• Second-line Treatment of Primary Autoimmune Hemolytic AnemiaRecruitingNCT05057468Phase 3
• A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingNCT04901936Phase 2
• The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After TratmentNot yet recruitingNCT04814394
• A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationNCT04138927Phase 3
• Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune CytopeniaRecruitingNCT04005638
• Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)TerminatedNCT04661033Phase 2Results posted
• To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).TerminatedNCT04253236Phase 2Results posted
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedNCT03764618Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03559699Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03548220Phase 3Results posted
• Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)CompletedNCT03226678Phase 2Results posted
• A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)TerminatedNCT03075878Phase 1/2Results posted
• A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyCompletedNCT02476916Phase 2Results posted
• Sirolimus for Autoimmune Disease of Blood CellsCompletedNCT00392951Phase 1/2Results posted
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedNCT00110617Phase 2Results posted
• Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy SubjectsCompletedNCT07040787Phase 1
• A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy SubjectsCompletedNCT06684041Phase 1
• CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.Active, not recruitingNCT06231368Phase 1
• A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)CompletedNCT06144749Phase 2
• An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedNCT05757570Phase 1/2
• Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.Status unknownNCT05711264
• A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisStatus unknownNCT05263817Early Phase 1
• Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusStatus unknownNCT05057481Phase 3
• The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic AnemiaCompletedNCT05004259Phase 1
• A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseCompletedNCT04987489Phase 2
• Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)TerminatedNCT04964323
• Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic AnemiaWithdrawnNCT04956276Phase 2
• Parvovirus B19 Infection in Hereditary Hemolytic Anemias PatientsStatus unknownNCT04822090
• Ferumoxytol Enhanced Hyperfine Low Field Strength MRICompletedNCT04721262
• A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Active, not recruitingNCT04624659Phase 3
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatActive, not recruitingNCT04610866Phase 1/2
• The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
• ALXN1830 in Patients With Warm Autoimmune Hemolytic AnemiaWithdrawnNCT04256148Phase 2
• Gene Therapy for Pyruvate Kinase Deficiency (PKD)CompletedNCT04105166Phase 1
• Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic AnemiaCompletedNCT04083014Phase 2
• Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.CompletedNCT04057703
• A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITPWithdrawnNCT04039477Phase 2
• Data Registry of Auto Immune Hemolytic AnemiaStatus unknownNCT04024202
• Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune CytopeniaWithdrawnNCT03965624Phase 2
• Tacrolimus Treatment for Refractory Autoimmune CytopeniaStatus unknownNCT03918265Phase 4
• Ibrutinib in Steroid Refractory Autoimmune Hemolytic AnemiaStatus unknownNCT03827603Phase 2
• Gall Bladder Status Among Children With Chronic Haemolytic AnemiaStatus unknownNCT03533322
• Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic AnemiaCompletedNCT03269292
• SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell PainCompletedNCT03006718Not applicable
• Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)CompletedNCT02828670
• Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseCompletedNCT02689986Phase 2
• The Role of Microparticles as a BiomarkerWithdrawnNCT02626663
• A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)CompletedNCT02612558Phase 2
• Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersCompletedNCT02502903Phase 1
• A Study Of Mircera In Patients With Kidney Disease Who Are Not On DialysisCompletedNCT02490514
• Immunoglobulin Dosage and Administration Form in CIDP and MMNCompletedNCT02111590
• Pyruvate Kinase Deficiency Natural History StudyCompletedNCT02053480
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Phase 2
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal HemoglobinuriaStatus unknownNCT01642979Phase 2
• Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.Status unknownNCT01579110Phase 2
• A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic AnemiaCompletedNCT01345708Phase 2
• Rituximab in Auto-Immune Hemolytic AnemiaCompletedNCT01181154Phase 3
• Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaCompletedNCT01134432Phase 3
• Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern IsraelCompletedNCT00971984
• Long Term Effects of Erythrocyte LysisCompletedNCT00842621
• Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasCompletedNCT00749112Phase 2/3
• Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)CompletedNCT00309881Phase 2
• Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic DiseaseCompletedNCT00010387Phase 2
• Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesStatus unknownNCT00006055Not applicable
• Combination Drug Therapy for Patients With Hepatitis CCompletedNCT00001729Phase 3
• Treatment of Autoimmune Thrombocytopenia (AITP)CompletedNCT00001630Phase 1

← Anemia, Hemolytic overview